Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
Several chemotherapeutics exert immunomodulatory effects. One of these is the nucleoside analogue gemcitabine, which is widely used in patients with lung cancer, ovarian cancer, breast cancer, mesothelioma and several other types of cancer, but with limited efficacy. We hypothesized that the immunop...
Main Authors: | W Joost Lesterhuis, Joanne Salmons, Anna K Nowak, Esdy N Rozali, Andrea Khong, Ian M Dick, Julie A Harken, Bruce W Robinson, Richard A Lake |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23626745/pdf/?tool=EBI |
Similar Items
-
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
by: Esdy N. Rozali, et al.
Published: (2012-01-01) -
Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
by: Wayne J. Aston, et al.
Published: (2019-11-01) -
A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice
by: Wayne J. Aston, et al.
Published: (2017-10-01) -
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.
by: Nobuhiro Nakamoto, et al.
Published: (2009-02-01) -
CTLA-4 blockade: therapeutic potential in cancer treatments
by: Ahmad A Tarhini, et al.
Published: (2010-03-01)